首页> 外文期刊>Journal of Cachexia, Sarcopenia and Muscle >Finding good biomarkers for sarcopenia
【24h】

Finding good biomarkers for sarcopenia

机译:寻找肌肉减少症的良好生物标志物

获取原文
           

摘要

The term sarcopenia describes the age-related loss of skeletal muscle mass and function. While this process, in principal, occurs in every adult person and already starts around the age of 40, it is associated with disability, morbidity, and increased mortality in some individuals. In the absence of clear clinical manifestation, we today lack the ability to differentiate between physiological and pathological sarcopenia. In this regard, we need good biomarkers that can be quantified in a reliable, cost-effective manner and that guide diagnosis and therapy of pathological sarcopenia in routine clinical practice and clinical trials. We suggest that a combination of serum markers, diagnostic imaging, and functional tests of muscle function would constitute an ideal biomarker panel. Importantly, sarcopenia biomarkers will have to be tested and validated in clinical trials.
机译:肌肉减少症一词描述了与年龄有关的骨骼肌质量和功能丧失。虽然此过程主要发生在每个成年人中,并且已经在40岁左右开始,但它与某些人的残疾,发病率和死亡率增加相关。在缺乏明确的临床表现的情况下,我们今天缺乏区分生理性和病理性少肌症的能力。在这方面,我们需要可以以可靠,具有成本效益的方式进行定量的良好生物标志物,并在常规临床实践和临床试验中指导病理性肌肉减少症的诊断和治疗。我们建议将血清标志物,诊断性影像学和肌肉功能功能测试相结合将构成理想的生物标志物组。重要的是,肌肉减少症生物标志物必须在临床试验中进行测试和验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号